PXS.L Stock: Provexis plc Stock Price, Analysis & Insights
Get live PXS.L stock price $0.94, comprehensive Provexis plc stock analysis, charts, news, and expert forecast. Real-time PXS.L stock data and investment insights.
Loading chart data...
Investment Score
A systematic tri-factor framework that integrates valuation, business quality, and market momentum into one investment signal. This helps investors triage opportunities faster, while surfacing risk regimes that may require tighter position sizing or deeper due diligence.
Score unavailable for this asset.
0-39
Defensive posture
40-54
Mixed / wait for confirmation
55-69
Constructive setup
70-100
Attractive zone
Total Score
Value
Cheapness vs fundamentals and cash generation
Quality
Durability of profitability and balance sheet
Momentum
Price trend strength and persistence
Company Overview
Operating globally, Provexis plc, along with its associated companies, specializes in the creation, licensing, and commercialization of functional foods, medical nutritional products, and dietary supplements. A key offering is Fruitflow, a unique tom...
Company Information
- CEO
- Ian Ford
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Employees
- 2
Contact Information
- Website
- https://www.provexis.com
- Address
- 2 Blagrave Street
- Country
- GB
Investment Analysis & Business Insights
Investment Highlights
✓ Strong presence in the Healthcare sector with established market position
✓ Lower volatility stock (Beta: 0.69) may provide portfolio stability
Important Investment Considerations
- ⚠All investments carry risk, including potential loss of principal for Provexis plc shareholders
- ⚠Market volatility can significantly impact stock price, especially for smaller companies
- ⚠Sector-specific risks in Healthcare may affect company performance
- ⚠Past performance does not guarantee future results for Provexis plc
- ⚠Investors should consider how Provexis plc fits within their overall portfolio allocation
Market Cap
22.05M
Beta
0.69
Data Sources & Methodology
Financial data on this page is sourced from verified SEC EDGAR filings (10-K, 10-Q, 8-K reports), real-time market data providers, and official company disclosures. All analysis is generated using AI models trained exclusively on reliable financial documents. For detailed information about our data sources and methodology, see our Methodology page.Not investment advice.
Related Stocks
Compare PXS.L with peer companies:
- Price
- $12.00-4.76% (1D)
- Market cap
- 2.32B
- Price
- $3.00+0.00% (1D)
- Market cap
- 1.57M
- Price
- $36.00+0.00% (1D)
- Market cap
- 1.68B
- Price
- $12.00-2.04% (1D)
- Market cap
- 1.50B
- Price
- $2.13-1.16% (1D)
- Market cap
- 1.20B
- Price
- $26.00+0.00% (1D)
- Market cap
- 2.33B
- Price
- $8.65+0.00% (1D)
- Market cap
- 804.93M
- Price
- $0.48+0.00% (1D)
- Market cap
- 395.33M
- Price
- $0.20+0.00% (1D)
- Market cap
- 426.17M
- Price
- $0.38+0.00% (1D)
- Market cap
- 567.52M
About Healthcare Sector
The Healthcare sector includes companies that provide medical services, develop pharmaceuticals, manufacture medical devices, and offer health insurance.
Healthcare (1D)
43/100 ⭐⭐⭐
- Overall
- -1.0%
- NYSE
- -1.6%
- NASDAQ
- -0.4%
| Sector | 1D | 1W | 1M | P/E | Score |
|---|---|---|---|---|---|
| Financial Services | +0.4% | +1.3% | +2.0% | 19.8 | 83/100⭐⭐⭐⭐⭐ |
| Technology | +0.8% | +1.1% | +3.0% | 52.0 | 76/100⭐⭐⭐⭐⭐ |
| Basic Materials | +0.8% | +0.3% | +1.9% | 27.9 | 69/100⭐⭐⭐⭐ |
| Industrials | -0.3% | -0.9% | +2.7% | 43.0 | 64/100⭐⭐⭐⭐ |
| Communication Services | -0.8% | -1.3% | +0.4% | 21.9 | 48/100⭐⭐⭐ |
| Consumer Defensive | +0.6% | +1.6% | -2.5% | 31.2 | 44/100⭐⭐⭐ |
| Healthcare | -1.0% | -2.0% | +1.5% | 30.5 | 43/100⭐⭐⭐ |
| Real Estate | +0.5% | -1.1% | -0.0% | 50.0 | 33/100⭐⭐ |
| Energy | +0.5% | -3.6% | -0.0% | 35.9 | 31/100⭐⭐ |
| Utilities | +2.0% | -1.3% | -5.1% | 26.1 | 31/100⭐⭐ |
| Consumer Cyclical | -0.3% | +0.3% | -0.2% | 55.8 | 28/100⭐⭐ |
Sector returns combine NYSE and NASDAQ averages. P/E is the latest blended sector multiple. Sector score ranks each sector vs peers using percentile ranks (not fixed thresholds): 48% 1M + 24% 1W + 8% 1D + 20% P/E (lower P/E ranks higher). Data as of 2026-06-12.